

CURRENT REPORT

Report date: **24.07.2025**

Name of issuing company: **Antibiotice SA**

Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**

<https://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

Important event to be reported:

CONVENING

OF THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS

The Management Board of Antibiotice S.A. reunited in the meeting on 24.07.2025, as per art. 117 of Law no. 31/1990 and art.16 of the company's Articles of Incorporation, correlated with Article 186 of ASF Regulation no. 5/2018, convenes on 26.08.2025, the **Ordinary General Meeting of Shareholders** at 10:00 a.m. at the company's head office in Iasi, Valea Lupului Street no. 1, with the following agenda:

1. Approval of the project entitled "Research and Development Center Inova a+ and critical medicines production" which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, "Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector" and the related expenses in value of 376,877,912.87 lei, VAT-free.

Antibiotice S.A. undertakes to ensure that it has the financial capacity to provide its own contribution to both the eligible and non-eligible project expenditures, under the conditions of subsequent reimbursement/settlement of the expenses. Antibiotice S.A. undertakes, for a 5-year period from the date of completion of the investment, in accordance with the state aid scheme and the provisions of Article 65 of Regulation (EU) No. 2021/1060, to maintain the investment made by covering the related operating and maintenance costs, as well as the necessary associated services, in order to ensure its financial sustainability.

2. Approval of the technical and economic indicators of the project entitled “Research and Development Center Inova a+ and critical medicines production”, which will be submitted for financing under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, conducted by Health Program Managing Authority” , Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector”.
3. Authorization of the Management Board to issue resolutions approving, based on supporting documentation, the exact amount of expenses related to the project “Research and Development Center Inova a+ and critical medicines production” and its technical-economic indicators which will be submitted for funding under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)” , Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector, provided they are kept within the maximum value of 376,877,912.87 lei, VAT-free.

The shareholders registered at the reference date can exercise their right to attend and vote at general meeting directly, by mail or by a representative with special or general power of attorney, according to the article 105 para. 7, of Law 24/2017 on issuers of financial instruments and market operations. The access of shareholders is allowed based on the identity card, special or general power of attorney, special power of attorney authenticated or mandate, for the legal representatives.

The original vote by mail form together with a copy of the identity card for the individual shareholders or any document certifying the capacity of legal representative for the corporate shareholders or statement of accounts shall be sent to the company headquarters until 24.08.2025, 10⁰⁰ a.m.

In accordance with the art. 105 para. (23³) of Law no. 24/2017 on the issuers of financial instruments and market operations and by applying the provisions of para. (23¹), the "abstention" position adopted by a shareholder regarding the items on the agenda of the General Meeting of Shareholders does not represent an expressed vote.

Starting with 25.07.2025, the special or general power of attorney, the mail voting form, the draft resolutions, as well as the materials and documents which will be the subject of deliberations will be available both in Romanian and English at the company's headquarters (Investor Relations - phone number: +40372.065.570 / +40372.065.583, fax: +40372.065.633, e-mail: relatiicuinvestitorii@antibiotice.ro) and on our company website ([www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/OGMS 26/27.08.2025](http://www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/OGMS%2026/27.08.2025)).

Until 24.08.2025, 10⁰⁰ a.m., the special or general power of attorney shall be submitted in original form, either in English or Romanian language, accompanied by a copy of the identity card or registration certificate of the shareholder represented, at the company's headquarters or sent via e-mail, with extended electronic signature. In the event that a shareholder mandates a credit institution which provides custody services, to attend and vote in the general meetings, only the original special power of attorney is needed accompanied by an original affidavit issued by the credit institution (according to the article 207 of the FSA Regulation no. 5/2018 on issuers of financial instruments and market operations).

One or more shareholders representing, individually or together, at least 5% of the Company's share capital has/have the right:

- a) to introduce new items on the agenda of the General Meetings of Shareholders accompanied by a justification or by draft resolutions proposed for approval by the General Meetings of Shareholders;
- b) to submit draft resolutions for new items included or proposed to be added on the agenda of the General Meetings of Shareholders.

The rights specified under the letters a and b can only be exercised in writing, the formulated proposals to be sent by courier services or by electronic means. Shareholders can exercise the rights specified under the letters a and b within 15 days from the date of publication of the Convening Notice in the Official Gazette of Romania.

In cases where the exercise of the right provided for in letter a) determines the modification of the agenda of the General Meeting already communicated to the shareholders, the company will make available a revised agenda, using the same procedure as that used for the previous agenda, before the reference date of the general meeting of shareholders, so that to allow the other shareholders to appoint a representative or, if applicable, to vote by mail.

The company's shareholders can ask questions regarding the items on the agenda of the General Meetings until 26.08.2025, 10⁰⁰ a.m., at the e-mail address: relatiicuinvestitorii@antibiotice.ro.

In all the above cases, with the exception of the special or general power of attorney granted by a shareholder to a credit institution which provides custody services, the legal entity shareholders prove their legal representative status, with the legal representative's identity card together with an ascertaining certificate issued by the Trade register, or any other document issued by a competent authority in the State where the shareholder is legally registered, which certifies the capacity of legal representative. The documents will be presented in original or in copy conforming to the original. The ascertaining certificate or the equivalent document attesting the legal representative capacity of the legal entity shareholder will be issued no later than 30 days before the date of the General Meeting of Shareholders. These documents certifying the capacity of legal representative drawn up in a foreign language, other than English, will be accompanied by a translation in Romanian or in English made by an authorized translator, without being legalized or apostilled (Art. 194 of Regulation 5/2018 on issuers of financial instruments and market operations).

In accordance with art. 198 and art. 199 of Regulation 5/2018 on issuers of financial instruments and market operations, in the case of shareholders who ask questions or make proposals to complete the agenda, they can attest their identity also by submitting the account statement which proves the shareholder status as well as the number of shares held, issued by the central depository or, as the case may be, by the indirect participants who provide custody services (according to art. 146 paragraph 4¹ of Law no. 297/2004).

More detailed information on shareholders rights can be accessed on the company's website (www.antibiotice.ro).

At this General Meeting of Shareholders, all the shareholders registered in the Shareholders Register by the end of 14.08.2025, established as reference date are entitled to attend and vote.

If the statutory quorum is not met for the validity of the deliberations at the first call, the General Meeting shall be rescheduled for 27.08.2025, at 10⁰⁰ a.m. at the same address and with the same agenda.

President of the Management Board,
Ionut-Sebastian IAVOR